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IT is n1ow well recognised that bone marrow depression is often the limiting
factor in the chemotherapy of malignant disease and that similar side effects may
complicate large volume radiotherapy. It seemed logical to suppose that if
these adverse effects could be modified or averted, then larger doses of anti-
tumour drugs could be employed or large volume radiotherapy carried to higher
levels of dosage. The well known effects of bone marrow cell infusion in labora-
tory animals suggested a possible attack on these problems in man.
It has been shown by the elegant experiments of Jacobson and his colleagues
in mice (Jacobson et al., 1949a, b; 1950) that protection against the lethal effects
of X-rays can be provided by splenic shielding. Similarly the aplasia produced
by large doses of mustine hydrochloride was averted by clamping the splenic
pedicle. Intra-peritoneal implantation of fresh splenic cells was also found to be
protective and Lorenz and his colleagues (Lorenz et al., 1951) obtained protection
against X-ray aplasia with repopulation of bone marrow using intravascular
injections of fresh bone marrow cells. Protection against lethal doses of alkylat-
ing agents was also provided by bone marrow cells injected intravenously (Weston
et al., 1.957; Talbot and Elson, 1958; Tran Ba Loc, Mathe and Bernard, 1958;
Dunjic and Maisin, 1960).
The clinical application ofthis animal work wasfacilitated by Barnes and Loutit
(1955) when they showed that infant mouse spleen preserved at -790 C. by the
cooling technique of Polge and Lovelock (1952) would protect irradiated mice.
Thus it was theoretically possible to preserve part of a patient's own bone marrow
and to reinfuse it later. This would obviate the necessity of using homologous
bone marrow with its lower efficiency (Lorenz et al., 1952), its danger ofproducing
secondary disease, (Barnes and Loutit, 1954 ; Mathe et al., 1960) and its ineffec-
tiveness after alkylating agents (Talbot and Elson, 1958 ; Tran Ba Loc et al.,
1958). Many workers have attempted homologous, isologous and autologous
bone marrow cell transplants in the human with varying degrees of success
(Kay and Koller, 1960). Following similar principles we have treated 52 cases,
29 ofwhom received autologous marrow and 23 homologous marrow cell infusions.
METHODS
(1) (ollection, storaye and administration of bone marrow cells in the huanan.-
Preliminary clinical trials (Humble and Newton, 1958) showed that it was possible
to aspirate 0-6-1-2 x 109 cells by conventional bone marrow puncture and that
such cell suspensions injected directly intravascularly seldom produced clinical
symptoms. Early attempts to preserve aspirated marrow by the Polge-Smith-D. E. PEGG, J. G. HUMBLE AND K. A. NEWTON
Parkes technique were unsatisfactory. On cooling the cell suspension the fat
formed a solid mass, trapping many of the bone marrow cells. This material
could not be injected directly into the patient without risk of fat embolism,
whereas filtration at this stage removed many ofthe bone marrow cells. Further-
more, apparatus available for this freezing technique was time consuming and
inconvenient. Apparatus and techniques for the collection, processing, storage
and administration of human bone marrow have already been described (Pegg and
Trotman, 1959; Pegg, 1960; Pegg and Kemp, 1960).
(2) Haematological Procedures.-Standard haematological techniques were
used throughout. Bone marrow cellularity was assessed by needle puncture
withdrawing no more than 0 5 ml. with the preparation of smears and total
nucleated cell counts. Myelograms were converted into absolute counts of
each cell type. A normal range was established by biopsy of unirradiated bone
marrow sites in 22 cases. The normal range was taken to be the mean ± two
standard deviations. In describing the recovery of the peripheral blood counts
of these patients we have used the term " beginning of recovery " to signify a
rise in the count to twice its lowest value when this rise subsequently continued.
The term " recovery " is reserved for restoration of the count to the normal
range. Marrow cell infusion doses are given in terms of actual marrow cells
corrected for leucocyte admixture.
Autologous Marrow Infusion in Wide Field Irradiation
Eight patients received total thoracic radiotherapy for multiple pulmonary
metastases, one patient received whole trunk irradiation for widely disseminated
metastases and one patient received whole body irradiation.
Results
The clinical and therapeutic details concerning these cases are shown in Table
I. Cases 1 to 9 were treated by the 2 MeV Generator and Case 10 by X-rays
generated at 250 kv. Cases 1, 2 and 4 received 300 r per day and developed
severe radiation pneumonitis. The remainder of the patients receiving total
thoracic irradiation were, therefore, given 140 to 150 r per day, but in spite ofthis,
Case 7, a male of 52 with a history of chronic bronchitis, also developed radiation
pneumonitis.
The pre-treatment blood counts revealed only minor departures from normalitv
in these cases. Leucopenia followed treatment in Case 7 alone; this patient had
previously received extensive radiotherapy to the pelvis and lumbar vertebrae.
In four cases (4 to 7 inclusive) it was possible to carry out a sternal marrow
biopsy immediately after the course of radiotherapy and in each case this showed
gross hypoplasia. Case 3 received an intravenous infusion of marrow freshly
aspirated from his unirradiated pelvis, but the remaining patients were infused
with marrow aspirated before treatment and stored at 790 C. The amount of
marrow infused varied between 3 and 133 x 106 marrow cells per kg. Sternal
marrow biopsies taken within 2-4 weeks of marrow infusion showed recovery to
mild hypocellularity (Cases 1 and 5), or even to the lower limits of normal cellu-
larity (Cases 2 and 7). Biopsies taken after 6-8 weeks usually showed complete
marrow recovery (Cases 1, 6 and 7), although one patient (Case 5) had persistent
mild hypocellularity. Case 9 received total trunk irradiation in a single treat-
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TABLE I.--Autologous Marrow Infusion in Wide Field Irradiation
Sex Diagnosis
F. Osteogenic
sarcoma
Ewings
tumour
M. Seminomna
M. Ewings
tumour
Ditto
F.
A.
Nephro-
blastoma
Seminoma
Ewings
tumour
Lympho-
sarcoma
Reticulum
cell
sarcoma
Total
radiation
dose
(r)
2708
2933
Daily
radiation
dose
(r)
300
Tumour
regression
No
300 Good
Radiation Survival Cause of
pneumonitis time death
Yes 13 weeks Radiation
pneumonitis
Yes 7 mnonths Ditto
2500 150 Fair No 16 days Broncho-
pneumonia
2950 300 Good Yes 6 months Radiation
pneumonitis
3058 150 No 2 years Pulmonary
metastases
2550 150 Alive at
3 years
2550 150 Fair Yes 12 weeks Radiation
pneumonitis
2550 140 Good No 8 months Cerebral
metastases
560 - 9 weeks Multiple
metastases
300-350 Fair 20 days Broncho-
pneumonia
ment session with minimal side effects. Half of his stored marrow was infused
4 days later, and the remaining half after a further 3 days. Recovery ofhis blood
count began 9 days after the first infusion and was complete 9 days later. Case
10 was treated by Dr. B. Jolles and is included with his kind permission. Total
body irradiation was administered in a single treatment session to a centre dose
of 300-350 r and the bone marrow, stored at 4° C., was given 2 hr. later. He
experienced a considerable leukopenia (Fig. 1), but recovery was rapid. The
response of the tumour in these 10 patients followed their established radio-
sensitivities.
I)iscussion
In the human, regional irradiation of bone marrow frequently results in
permanent hypoplasia of the treated area and this may be an important limiting
factor in clinical radiotherapy. Assessment of the radiation dose absorbed by
the bone marrow is a very complex problem, particularly when 250 kv radiation
is used, and it is doubtful if accurate corrections can be made on a theoretical
basis. Most of the authors specify radiation in skin doses, but several factors,
including the superficial position of the marrow cavities sampled and secondary
electron emission at 250 kv, make it rather unlikely that the bone marrow doses
were less than 75 per cent of the skin doses.
Denstad (1943) found that complete recovery was unusual when the total
skin dose, conventionally fractionated, exceeded 3000 r. Stewart and Dische
(1956) and Stewart (1958) found that after 2000 r of fractionated radiation to the
skin, recovery of the underlying bone marrow was not evident for 8-10 weeks and
was often incomplete. After 4000 r aplasia was permanent in 50 per cent of
cases and recovery in the remainder was slow and incomplete. The data of
Sykes et al. (1959, 1960) confirm that the first signs of recovery after 4000 r are
Case
1
2
3
4
5
6
7
8
9
10
Age
21
21
49)
19
20
5
52
8
17
27
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not usually seen until 2 months have elapsed and that complete eventual recovery
is exceptional.
The dosage schedules used in standard radiotherapy procedures which involve
irradiation ofthe sternum are quite different from those used in the present study,
so that precise controls could not be obtained. Nevertheless it seems to be clear
that the radiation doses used in these patients would have produced prolonged
hypoplasia of the thoracic marrow in a high proportion of cases.
In 5 of our patients it was possible to obtain the marrow biopsies needed to
establish the rate and extent of sternal marrow repopulation. Normal cellularity
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FIG. 1.-Case 10.-Effect of autologous marrow infusion in a patient
receiving whole body radiotherapy.
was achieved in 4-8 weeks in 4 of them; the remaining case (No. 5), had some
residual hypoplasia. It seems, therefore, that recovery was more rapid and more
complete than would have occurred without marrow infusion.
It is well known that total haemopoiesis is not affected by local irradiation of
quite large volumes (Denstad, 1943; Tubiana et al., 1959). This is confirmed
by the lack ofleukopenia and thrombocytopenia in Cases 1-6 and 8 ofthe present
series. Irradiation of the whole trunk or whole body, however, (Cases 9 and 10)
did result in serious leukopenia. These patients recovered a normal white cell
count in the remarkably short times of 18 and 14 days respectively. The time
taken for complete recovery of the peripheral blood after 300-350 rads of total
body irradiation is not altogether certain. The experience of accidental irradia-
tion (Andrews et al., 1959; Jammet et at., 1959) suggests that 50-60 days might
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be a reasonable estimate. It seems probable, therefore, that the speedy recovery
of our case was assisted by the marrow infusion. However, there are features
of the accidental irradiation, particularly its lack of homogenicity and large
neutron component, which suggest that the two situations may not be strictly
comparable.
In this series it was not possible to demonstrate a relationship between the
rapidity or extent of sternal marrow repopulation with the number of marrow
cells infused; 6 of the patients received more than the acceptable minimum
autologous marrow cell infusion (11 x 106 cells/kg., Pegg, 1962); the 4 patients
who received less than this (Cases 2, 3, 5 and 7) had only thoracic irradiation. It
is possible that less marrow is required to reseed locally aplased bone marrow than
is needed for whole body radiation protection.
Autologous Marrow Infusion in Anti-tumour Chemotherapy
Nineteen cases were studied.
Results
In all the patients in this study the malignant disease was in a very advanced
state ; they were divided into six groups, each receiving a different alkylating
agent. With each drug, either the speed of administration, or the total dose, or
both, were increased above the usual treatment schedules (Table II).
Group 1. Mustine Hydrochloride (5 patients, Cases 11-15). The total doses
were between two and four times as great as those commonly employed and the
course lasted a very much shorter time than is usual. General toxic effects of
the treatment were prominent andincludedsevere nausea andvomiting, pulmonary
oedema, hallucinations, deafness, pyrexia, diarrhoea and alopecia. Intravenous
infusions of stored autologous bone marrow were given in all cases within 3 days
of the completion of treatment, but in spite of this, all but 1 patient developed
severe leukopenia and thrombocytopenia. One patient received 0 8 mg./kg. of
mustine hydrochloride by lower limb perfusion, followed 7 hr. later by the intra-
venous infusion of autologous bone marrow stored at + 40 C. He suffered no
more than a transient lymphopenia. The treatment was carried out after full
surgical excision and there has been no recurrence in 2 years. Two patients died
within 4 days, but the remaining 2 patients showed the beginning of recovery as
defined above, by the 8th and 11th days respectively. One patient survived 80
days and had regained a normal leucocyte count on the 30th day (Fig. 2). Tumour
regression was disappointingly meagre.
Group II. Mannomustine dihydrochloride (6 patients, (Cases 16-21). The
patients in this group also received between 2 and 4 times the usual dose of the
drug which was administered in one-half to one-third of the usual time. In spite
of this, toxic effects were limited to mild nausea in one case and minimal drowsi-
ness in another. In all cases there was severe leukopenia and thrombocytopenia.
The first patient treated with this agent received an infusion of stored autologous
bone marrow 24 hr. after the completion of treatment, but in order to allow a
longer time for elimination ofthe drug as well as to permit more complete emptying
of the marrow spaces, the remaining patients received their marrow infusions
as soon after 4 days as their leucocyte count fell below 1000/cu.mm. Fig. 3
shows a typical response, illustrating well the much slower fall in the leucocyte
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TABLE II.-Autologous Marrow Infusion in Anti-tumour Chemotherapy
Bone marrow
infusion
Interval Interval
between from Survival timne
end of Number marrow -
chemo- of infusion Measured
Chemotherapy therapy marrow to from
, and cells begin- end
Age Total Duration Tumour bone infused ning of chemo-
Case and dose of regres- marrow (x 106/ recovery therapy Cause of
No. sex Diagnosis mg/kg. course sion infusion kg.) (days) (days) death
Mwuine hydrochloride. Administered by intermittent intravenous injection except for Case 15 who received a limb
perfusion
11 56 F. Carcinoma 1-85 15 hours No 3 days 2 7 Broncho-
oesophagus pneumonia
12 32 M. Malignant 1-30 3 days Slight 3 ,, 6 - 5 Ditto
melanoma
13 34 F. Ditto 1.10 11 hours No 2-5 hours 36 11 15 Pulmonary
metastases
14 39 ,, ,, 100 30 min. Slight 6-0 ,, 22 8 80 Cerebral
metastases
15 42 M. ,, 0-80 25 ,, - 7-0 ,, 130 Alive
without
recur-
rence 2
years
later
Mannomustine hydrochloride. Administered by intermittent intravenous injection
16 40 F. Malignant
melanoma
17 45 M. Ditto
18 12 ,, Hodgkin's
disease
19 36 ,, Malignant
melanoma
20 64 F. Ditto
65 5 days Good 1 day
47 6 ,,
38 2 ,,
47 23
50 26
Slight 20 days
No 4 ,
Slight 11 ,
No 7 days
15 days
9
36
8
103
50
21 62 ,, Carcinoma 20 10 ,, ,, 15 ,, 83
caecum
Cyclopho8phamide. Administered by intermittent intravenous injection
22 52 F. Ovarian 40 9 days No 5 days 14
carcinoma
23 21 M. Ewing's 165 48 hours Good 7 ,, 19
tumour
24 67 ,, Carcinoma 67 25 ,, Good 4 ,, 55
body of
uterus
25 42 F. Pulmonary 67 26 ,, No 6 ,, 4
carcinoma
Phenylalanine mu8tard. Administered by continuous intravenous infusions
26 34 F. Malignant 2 30 7 days Good 50 days 13
melanoma
27 39 ,, Ditto 0-96 24 hours Fair 6 ,, 41
N-Deacetyl thiocolchicine. Administered by continuous intravenous infusion
28 34 F. Malignant 1-70 24 hours Good 3 days 6
melanoma
Triethyleneglycol diglycidyl ether. Administered as a single intravenous injection
29 34 M. Malignant 300 5 min. No 12 days 26
melanoma + and
20 days 14
- 8 Cerebral
haemorrhage
7 84 Cerebral
metastases
11 Myocardial
necrosis
5 21 Cerebral
haemorrhage
6 16 Broncho-
pneumonia
4 78 Vena Caval
thrombosis
2 126 No autopsy
7 277 Pulmonary
metastases
9 Pulmonary
metastases
4 180 No autopsy
12 180 See Case 28
7 Broncho-
pneumonia
4 63 Haemorrhage
into cerebral
metastases
13
from
1st
91 Pulmonary
metastases
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FIG. 2.-Case 14.-Effect of autologous marrow infusion in a patient
receiving 1 mg./kg. of mustine hydrochloride.
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FIG. 3.-Case 17.-Effect of autologous marrow infusion in a patient
receiving 47 mg./kg. of mannomustine hydrochloride.
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and platelet counts when comparison is made with mustine hydrochloride, and
the rapid recovery after autologous marrow infusion. Three cases died before
recovery was complete, two as a result of haemorrhage into necrotic cerebral
metastases and one from myocardial necrosis. Tumour regression was greater
than with mustine hydrochloride, but was still very disappointing.
Group III. Cyclophosphamide (4 patients, Cases 22-25)-The total doses of
this drug were not remarkable, but the rate at which it was administered was
increased up to twentyfold. Side effects were not prominent except in case 23,
.S.PTAAM#UWON:
_X~~~~~~~~~~~W
40i
100
who received 9X6 grams in 48 hr. This produced nausea and vomiting and severe
limb cramps. Alopecia occurred in all patients who survived longer than 2 weeks.
Infusions of stored autologous marrow were again given as soon after 4 days as
leukopenia was apparent and very rapid recovery was seen in three patients (Fig.
4); Case 24 died as a result of her pulmonary metastases on the 5th post-infusion
day. Good tumour regression was seen in 2 cases (Ewings tumour and pulmonary
carcinoma), but the remaining 2 showed no response.
Group IV. Phenylalanine Mustard (2 patients, Cases 26 and 27) This drug
was administered by continuous intravenous injection, a technique which seems
to result in a distinct increase in clinical effectiveness. Because of this increase
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in toxicity no precise comparison with divided dosage is possible. Leucopenia
developed in both patients and was treated by injection of stored autologous
marrow. One patient died as the result of her disease on the following day,
but the other patient showed improvement in her leucocyte count following the
infusion (Fig. 5). Both patients showed encouraging tumour regression.
Group V. N-deacetyl thiocolchicine (1 patient, Case 28) The dose used was
about 12-times the normal daily dose. but only one-quarter of the normal dose
1 t
O la 20 30 40 so 60 70
E.ChMTHERAP
TIME DAYS
FIG. 5.- Case 26.---Effect of autologous marrow in-fusion in a patienit
receiving 2- 3 mg./kg. of phenylalanine mustard.
for a complete course. Alopecia developed 3 weeks later. Severe leucopenia
and thrombocytopenia followed rapidly, and the marrow infusion was given after
3 days; it was followed by speedy recovery of the blood counts.
Group VI. Triethyleneglycol Diglycidyl ether (1 patient, Case 29)-Injection
of 300 mg./kg. into a running saline infusion produced dizziness and confusion
lasting 2 or 3 minutes, and mild nausea which lasted for 2 days. This dose was
about 50 per cent greater than that commonly employed. The treatment was
followed by leucopenia and thrombocytopenia, taking about 2 weeks to reach
minimum values and the bone marrow at this time was grossly hypoplastic, the
only remaining cells being lymphocytes, plasma cells and reticulum cells. Stored
autologous bone marrow was given at this time and both bone marrow and blood
were normal in 3 weeks.
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Di8scussion
The precise recovery rates to be expected from the treatment schedules used
in these cases is largely a matter of conjecture, since similar doses have not been
used without some method of marrow protection. Clearly it would not be
justifiable deliberately to obtain controls.
Group I. Mustine hydrochloride. Our personal experience of rapidly ad-
ministered mustine hydrochloride is limited to single-shot intra-aortic injections
of 0 3 mg./kg. These patients experience a moderate leucopenia with recovery
beginning on the 12th or 13th day. Block et al. (1948) reported that the leuco-
penia following 0-4 mg./kg. administered in 4 days occurs in the 3rd week follow-
ing treatment, and usually lasts for rather less than a week. One case, who
received 0 86 mg./kg. in 7 days, suffered a leucopenia of 500 cells/cu. mm. and did
not recover a normal count until the 12th week. Dameshek et al. (1949) using
rather smaller doses also noted the maximum leucopenia in the third week with
restoration to normal in 5-6 weeks. Bierman et al. (1949) described the haemato-
logical effects of larger single doses of mustine hydrochloride (0X6 mg./kg.);
the maximum leucopenic effect was seen in 11-16 days with recovery in 34-38
days. The rate of recovery in cases 13 and 14 was more rapid than any of these
in spite of the much larger doses of mustine being given.
Comparison with the cases reported by Conrad and Crosby (1960) shows that
the protection offered is comparable to that provided by the use of orthopaedic
tourniquets on the limbs during chemotherapy.
It was surprising to find so little blood count depression after perfusing 0 8 mg./
kg. in Case 15. Austin et al. (1959) found that the perfusion of this dose with a
systemic leak of 2'5 per cent per minute (the measured leak in Case 15) resulted
in leucopenia to about 1000/cu. mm. and thrombocytopenia to about 100,000/
cu. mm. In two cases studied personally the perfusion of 0-8 mg./kg. resulted
in leucopenia with recovery to pre-treatment levels in 3-4 weeks. It seems certain
therefore that autologous marrow infusion helped to prevent excessive haemo-
poietic depression in this case.
Group II. Mannomustine dihydrochloride.-In a series of 24 patients receiving
normal courses of mannomustine, white cell depression occurred whenever the
dose rate exceeded 0-7 mg./kg./day and a cumulative total of 9 mg./kg. was
exceeded. Recovery to pretreatment values took 2-3 weeks from the minimum
leucocyte count. This finding is in agreement with the observations of others
(Sellei and Eckhardt, 1958; Barlow et al., 1959). These authors emphasise the
prolonged marrow depressant effect of this drug; bone marrow smears made 6-8
weeks after treatment may still be hypoplastic. For this reason, Sellei recom-
mended that a second course should not be given for 6 months. These comments
apply to conventional treatment schedules: in the present series, in spite of the
much higher doses, recovery was complete within 7 days of the minimum count
in each case a striking contrast. There was significant correlation between
the recovery time and the number of marrow cells infused (r 0 816, p lies
between 0*05 and 0.02) although the correlation between the recovery time and
the drug dosage (r 0.768) was not significant (p lies between 041 and 0.05).
Biopsies showed that the bone marrow was virtually normal in cellularity by the
second week after the infusion.
Group III. Cyclophosphamide.-Recovery from the effects of this drug is
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extremely rapid even in the absence ofmarrow infusion. In a series of 14 patieints
receiving conventional doses of this drug, 6 patients experienced a leukopenia
below 1000 per cu. mm. and in each case the count returned to 2000 and con-
tinued to rise within 10 days. Nissen-Mayer and Host (1960), Stoll and Matar
(1961) and Anders and Kemp (1961) also noted the startling difference in speed
of recovery when this agent is compared with most other alkylating agents. In
view of this rapid recovery, it was considered safe to pair Case 25 with a similar
FIG. 6. Recovery of leucocyte count in Case 25 who received 67 mg./kg. of cyclophosphamide
and autologous bone marrow, contrasted with a control patient who received 67 mg./kg. of
cyclosphosphamide without a marrow infusion.
patient who would receive the same dose ofcyclophosphamide, but no bone marrow
infusion. This patient experienced a rather less severe leukopenia, but recovery
occurred at a comparable time and rate (Fig. 6). Case 23 received twice as much
cyclophosphamide and recovery occurred 2 days later than in the other cases,
but was again at the same rate. Although the infused marrow may have helped
this patient, it must be concluded that substantial benefit from marrow infusion
after this drug cannot be demonstrated.
Group IV. Phenylalanine mustard.-The haematological behaviour of
control patients receiving the same dose of alkylating agents as Case 26 has been
studied and there was no evidence of an increased rate ofperipheral blood recovery
when the marrow infusion was given.
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Group V. N-deacetyl thiocolchicine.-N-deacetyl thiocolchicine has been
used without autologous marrow infusion in a dosage of 09 mg./kg.: the sub-
sequent depression and recovery of the blood picture was remarkably similar
to that observed in Case 28. In view ofthe considerable difference in drug dosage,
it seems possible, but by no means certain, that the marrow infusion accelerated
the recovery of this patient.
Group VI. Triethyleneglycol diglycidyl ether.-This drug has been given in
approximately one half ofthe dosage used here, to 2 patients who did not receive
bone marrow infusion. The leucopenia was less severe, but recovery began at
about the same time as it did in Case 29. According to Innman (1962, personal
communication) recovery after 300 mg./kg. would be expected to take 28-32
days. It seems probable therefore that the marrow infusion accelerated recovery
by a few days.
In the whole series, 13 patients received more than 11 x 106 marrow cells/kg.
in the infusion. The 6 patients who received less than this either failed to recover
(Cases 11, 12, 16 and 18) or had received more moderate drug dosage, in which
case large marrow infusions would not be expected to be so important (Cases
25 and 28).
Homologous Marrow Infusions
Twenty-three patients were studied.
Results
Details of the attempted bone marrow homografts are given in Table III.
Cases 30-37 were suffering from naturally occurring bone marrow hypoplasias
of various types. Two patients received preliminary treatment designed to
increase the chance of a successful graft; Case 31 received total body irradiation
and case 35, regional irradiation and intravenous mustine hydrochloride.
Although there was some haematological improvement in 5 of these 8 cases, in
no case was it sufficiently impressive to suggest a successful graft. The poly-
morph nuclear sex tag was available for study in Cases 35 and 37 and chromo-
somal analysis for the presence of donor (male) cells in the peripheral blood was
carried out in Case 33; none ofthese cases provided any evidence ofa functioning
marrow graft.
Cases 38-47 were suffereing from bone marrow hypoplasia due to cancer
therapy. Preliminary regional irradiation was given to 2 patients (Cases 38 and
40). Five patients showed some improvement following the marrow infusion,
but this was probably not significant in Cases 38 and 44, and in Cases 45-47 the
recovery was no more rapid than would be expected in the absence of marrow
infusion. Erythrocyte antigen tags were followed in Cases 46 and 47, and the
nuclear sex tag in Cases 43 and 44; no case showed any evidence of a successful
homograft.
Cases 48-52 were all suffering from malignant disease and were treated par-
ticularly energetically, knowing that homologous marrow would be available
for infusion. The 2 patients suffering from chronic lymphatic leukaemia were
both benefited by the radiotherapy, particularly Case 48. Cases 50 and 51,
children with acute leukaemia, were subjected to total body irradiation and
homologous marrow infusion. Case 50, who received marrow 30 minutes after
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TABLE III.-Homologous Marrow Infusion
I
Case
!To. Age Sex Diagnosis
30 24 Chloramphenieol None
induced aplastic
anaemia
31 54 Y Aplastic anaemia Total
? chlorampheni- irrad
col induced
32 5 y Chloramphenicol None
induced aplastic
anaemia
33 74 $ Idiopathic None
aplastic anaemia
34 66 $ Aplastic anaemia None
probable toxic
aetiology
35 67 <3 Myeloid meta- Irradit
plasia ? toxic and f
aetiology Must
chlor
36 1 9 Acute lympho- None
blastic
leukaernia
37 30 ,3 Lymphosarcoma None
38 25 Hodgkin's
disease
39 11 c3 Lymphosarcoma
and leukaemia
40 14 y Neuroblastoma
41 38 y Hodgkin's
disease
42 59 Anaplastic
sarcoma of
lymphoid tissue
43 64 d Lymphosarcoma
44a 30 CT
44b 30
Acute monocytic
leukaemia
Ditto
45 49 Y Carcinoma of
stomach
rreatment
preceding
marrow
infusion
Bone
marrow
infusion
48 x 106
cells/kg.
Source
of
marrow
*
body 29 x 106 Daughter
liation 200 rads cells/kg.
290x 106 Mother
cells/kg.
84x106 Son
cells/kg.
51 x 106 Grandson
cells/kg.
iation of pelvis
femora and
line hydro-
ride
Radiotherapy,
Triethylene
thiophosphoramide,
Mustine hydro-
chloride and
Chlorambucil
Radiotherapy,
Amethopterin and
6-Mereaptopurine
Radiotherapy
Radiotherapy,
Mannomustine
hydrochloride and
Chlorambucil
Radiotherapy and
Mannomustine
hydrochloride
Radiotherapy,
Chlorambucil and
6-Mercaptopurine
6-Mercaptopurine
Mustine
hydrochloride
46 48 y Ovarian Radiotherapy and
carcinoma Cyclophosphamide
11 x 106 Daughter, 6
cells/kg. brother,
and
nephew
350 x 106 Grand-
cells/kg. father
43x106 *
cells/kg.
16 x 106 Mothe
cells/kg. and
brothe
9 x 106 Mothe
cells/kg.
30 x 106 Fathei
cells/kg. and
mothe
32x106 *
cells/kg.
15X106 *
cells/kg.
16x106 *
cells/kg.
11X106 *
cells/kg.
48 x 106 Wife
cells/kg.
23x106 *
cells/kg.
41 x 106 Sister
cells/kg.
Survival
time
47 days
8 ,,
16
Improvement
following
marrow infusion
Platelet count rose
from 40,000/cu. mm.
to 130,000/cu. mm.
in 4 days
Blood counts improv-
ing at time ofdeath
None
4 months Improved sternal mar-
row cellularity
6 weeks None
) days Leucocyte count rose
from 430/cu. mm.
to 2,000/cu. mm.
in 40 days
4 weeks Transient slight im-
provement of plate-
let count
6 months None
3 days Leucocyte count rose
from 4500/cu. mm.
to 6500/cu. mm. in
3 days
8 days None
15 min. None
ar
er
3r
Lost to
follow-up
at
1 month
11 days
None
None
6 days None
4 months None
2 months The platelet count
rose from 30,000/cu.
mm. to a maximum
of 100,000/cu. mm.
in 23 days
11 days Leucocyte count rose
from 300/cu. mm. to
13,000/cu. mm. in 9
days
3 months Leucocyte count rose
from /cu. mm. to
4000/cu. mm. in 14
days
I
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TABLE III-cont.
Case
No. Age
47 45
Sex Diagnosis
9 Carcinoma of
breast
Treatment
preceding
marrow
infusion
Radiotherapy and
Triethylene
thiophosphoramide
48a 66 y Chronic lym- Pelvic irradiation
phatic leukaemia 2500 rads in
20 days
48b 67 $ Ditto Lower half body
irradiation, 520
rads in one
treatment
49 56 d Ditto Total body irradia-
tion in two half-
body fractions of
800 rads
50 8 <3 Lymphosarcoma Total body irradia-
and leukaemia tion, 500 rads
51 6 9 Acute lympho- Total body irradia-
blastic leukaemia tion, 1160 rads in 8
half-body fractions
52 12 CT Hodgkin's
disease
Bone
marrow
infusion
174x 106
cells/kg.
Source
of
marrow
Son
17x10 Sons and
cells/kg. daughters
22x106 *
cells/kg.
144 x 106 *
cells/kg.
40 x 10 Mother
cells/kg.
67 x 106 Father
cells/kg.
Mustine hydro- 79 X 106 *
chloride 0-6 mg./kg. cells/kg.
in 3 days
* Ribs removed at thoracotomy and marrow stored at - 790 C.
Survival
time
10 ,
16 ,,
Improvement
following
marrow infusion
Leucocyte count rose
from 400/cu. mm. to
4000/cu. mm. in 30
days
None
12 days None
3 months None
23 days None
14 days Both leucopenia and
thrombocytopenia
improving at time of
death
3 months Leucocyte count re-
covered from a mini-
mum of200/cu. mm.
to 3000/cu. mm. in
28 days
the irradiation, failed to show any recovery by the 14th day. He was then given
a foetal liver infusion but still failed to respond and died with bone marrow aplasia
on the 23rd day. Active tumour tissue was in evidence at the autopsy. Case 51
was slightly more successful.
This child was treated at the beginning ofthe second relapse: two remissions
had been obtained previously with amethopterin and 6-mercaptopurine respec-
tively, Prednisone having been given throughout. Whole body irradiation was
administered with the 2 MeV X-ray generator in daily half-body fractions, each
halfreceiving 4 treatments at 2-day intervals. The total centre dose was 1160 r.
The equivalent single exposure was clearly less than this, and an estimate based
on the studies ofElkind and Sutton (1959) indicated an equivalent ofabout 860 r.
Bone marrow was administered 3 days after the last radiation fraction to allow
good time for aplasia to develop. Serial blood counts (Fig. 7) indicated the begin-
ning of recovery at about 7 days after infusion. At the time of death, 14 days
from the infusion, the platelet count had reached 153,000 per cu. mm. The
cause of death was an overwhelming monilial infection of the oesophagus and
stomach, and E. coli septicaemia.
The speed of the recovery of the blood count of Case 52 after treatment with
mustine hydrochloride was probably no more rapid than it would have been
without the marrow infusion. The female neutrophil tag was applicable to
Cases 49, 50 and 52, and in Case 49 female polymorphs were, indeed, detected
between the 42nd and 45th day after the infusion. Red cell antigen studies were
also applied to this case, but without any evidence of a functional graft.
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Discussion
Haematological improvement was observed in 12 of these 23 cases, but only
in Case 51 was it sufficiently rapid to suggest a successful homograft. Studies
of blood group antigens, polymorphonuclear sex and leucocyte chromosome
configuration provide a much more satisfactory test for the " take " of bone
marrow grafts, but except for the brief appearance of female polymorphs in one
case, these tests also failed to detect successful marrow homografts. In fact,
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FIG. 7.-Case 51.-Effect of homologous marrow transfusion in a case of acute leukaemia who
received 1160 r (fractionated) of whole-body irradiation.
only 4 cases received infusions which satisfied the minimum requirement of
130 x 106 cells/kg.: one ofthese patients-Case 49-was the only case to provide
evidence of a successful homograft.
We must conclude that attempts to produce marrow homografts in these
patients probably succeeded temporarily in one case and were perhaps successful
in another. In neither case was the procedure beneficial to the patient.
The Place of Marrow Infusion Treatment in Clinical Medicine
The place of autologous marrow infusion in clinical radiotherapy rests on
many factors besides the purely haematological considerations which have been
our principal concern thus far, and it seems that the usefulness ofwhole body and
whole trunk irradiation in association with autologous marrow infusion is severely
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restricted: rapidly growing tumours recur so soon that useful remissions are not
obtained. It is possible that the treatment may be indicated in widely dissemina-
ted, moderately rapidly growing lymphoid tumours and seminomata. The use
of autologous marrow infusions in the treatment of marrow aplasia caused by
regional irradiation was intended to increase the patient's total bone marrow
reserve ; this could be important should subsequent courses of treatment be
needed.
Before considering the place of autologous marrow infusion in association with
cancer chemotherapy, it is important to emphasise that there are very significant
differences between the effects ofalkylating agents and those ofionising radiation.
One such difference is that the margin of dosage separating " marrow death "
from intestinal death or other lethal effects is very slight ; this is referred to further
below. Another difference is that bone marrow regeneration is usually much
more rapid after chemotherapy. In the case of cyclophosphamide the speed of
natural recovery is so rapid that marrow infusion has no detectable effect even
at very high doses. After mustine hydrochloride the recovery is somewhat
slower and an acceleration of regeneration is possible after large doses, although
the more rapid recovery after low doses renders marrow infusions ineffective
(Smiley et al., 1961). However it is only after drugs like mannomustine which
produce prolonged leucopenia that obvious benefit comes from autologous marrow
infusion. The principal indication for autologous marrow infusion in cancer
chemotherapy is provided by the occurrence of severe leucopenia and thrombo-
cytopenia after treatment with an agent known to have a prolonged effect.
It is usually accepted that chemotherapy should be controlled in such a way
as to avoid severe bone marrow depression. When autologous marrow infusion
is introduced as a planned procedure, this policy is abandoned and severe bone
marrow depression is deliberately induced in the hope that greater tumour re-
gression will occur. Such a procedure is indeed precarious, for one is treating
patients in the narrow zone of dosage which separates severe bone marrow de-
pression from lethal systemic toxicity. And this is not the only problem.
The necessity to wait for the majority of the drug to be eliminated means that the
course of treatment must be short, otherwise the patient is exposed to the dangers
of leucopenia and thrombocytopenia at a time when the marrow cannot be in-
fused. This has introduced an additional severe limitation to the technique,
for it is now becoming increasingly clear that the most effective tumour response
is often obtained with protracted therapy. Certainly, none ofour patients showed
a degree of tumour regression greater than any we have seen in similar patients
receiving prolonged low dosage chemotherapy. As a deliberate part of a planned
treatment, it is indicated only ifthe drug which is used is one which produces pro-
longed haemopoietic depression. In addition, however, we have considered it
wise to use the technique as an " insurance policy " when new drugs and treatment
schedules are being explored and unintentional bone marrow depression is an
ever-attendent risk. It is established that autologous marrow infusion can
produce acceleration of marrow regeneration and that this may indeed be very
considerable in special circumstances. Lajtha (1960) and others have postulated
that conservative measures, including platelet transfusions, antibiotics and barrier
nursing, can help these patients. The available animal experimental evidence
as well as considerable clinical experience show that such measures do not posses
the potency of autologous marrow infusions in these cases.
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Homologous marrow infusions have been used in the treatment of aplasic
anaemia, bone marrow hypoplasia induced by cancer chemotherapy and leukaemia
after whole body irradiation. We have been wholly unsuccessful in benefiting
any ofthese patients, but at the present time the antigenic barriers which prevent
acceptance of homografts are largely unknown and further experience may alter
the position. The work ofHewitt and Wilson (1959, 1960) has shown conclusively
that there is no theoretical justification for the treatment of acute leukaemia by
large doses of whole body irradiation and homologous marrow infusion, while
the reports of Mathe and his collaborators (Mathe et al., 1960) have emphasised
that there is a danger of producing secondary disease in these patients. The
lack of success obtained so far merits the application of this technique only in
particularly desperate circumstances (Bielby et al., 1960; Mathe et al., 1959).
SUMMARY AND CONCLUSIONS
1. Eight patients have been treated with total thoracic irradiation to 2500-
3058 r and have subsequently received intravenous infusions of stored autologous
bone marrow. Sternal bone marrow recovery has been somewhat increased by
this procedure.
2. One patient receiving trunk irradiation to a dose of 560 r recovered rapidly
after autologous marrow infusion.
3. One patient receiving total body irradiation to a centre dose of 300-350 r
showed rapid recovery after autologous marrow infusion.
4. In a study of nineteen patients treated with chemotherapeutic agents
it was found that in those who had received large doses of mustine hydrochloride
and mannomustine dihydrochloride, the rapidity of haematological recovery was
increased, and aless markedbenefit wasnotedinpatients treated with N-deacetyl-
thiocolchicine and triethyleneglycol diglycidyl ether. In those cases treated
with cyclophosphamide and phenylalanine mustard, no benefit from autologous
marrow infusion was detected with the doses employed.
5. Twenty-three patients received homologous marrow infusions. Twelve
showed subsequent improvement of the blood picture, but this was not due to
successful bone marrow homografts. Successful, albeit transient, grafting
occurred in one case. A second patient probably had a " take ", but she died
before proof could be obtained.
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